VistaGen Therapeutics (VTGN) News Today $2.06 -0.32 (-13.45%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.08 +0.02 (+0.97%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period What is William Blair's Forecast for VTGN Q1 Earnings?VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - William Blair issued their Q1 2027 earnings per share estimates for VistaGen Therapeutics in a research note issued on Wednesday, June 18th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.37) fJune 19 at 7:40 AM | marketbeat.comVistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William BlairWilliam Blair reiterated an "outperform" rating on shares of VistaGen Therapeutics in a report on Wednesday.June 18 at 10:11 PM | marketbeat.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...June 18 at 4:22 AM | finance.yahoo.comVistagen Therapeutics Reports Progress in Clinical TrialsJune 18 at 12:26 AM | tipranks.comVistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call TranscriptJune 17 at 7:10 PM | seekingalpha.comVistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSVistagen Therapeutics (NASDAQ:VTGN - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.10. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%.June 17 at 5:06 PM | marketbeat.comVistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateJune 17 at 4:30 PM | businesswire.comInsights into VistaGen Therapeutics's Upcoming EarningsJune 16 at 10:43 AM | benzinga.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look ForJune 16 at 8:51 AM | gurufocus.comVistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025June 12, 2025 | businesswire.comVistagen Therapeutics (VTGN) to Release Earnings on TuesdayVistagen Therapeutics (NASDAQ:VTGN) will be releasing its Q4 2025 earnings before the market opens on Tuesday, June 10. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-6-10-vistagen-therapeutics-inc-stock/)June 3, 2025 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average - Should You Sell?May 28, 2025 | marketbeat.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comRenaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)Renaissance Technologies LLC trimmed its holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 56.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,700 shares of the company's stock aMay 8, 2025 | marketbeat.comAlmitas Capital LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)Almitas Capital LLC bought a new stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 254,655 shares of the company's stock, valued atMay 4, 2025 | marketbeat.comVistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Bought by Nantahala Capital Management LLCNantahala Capital Management LLC raised its position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 30.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,981,980 shares of the company's stApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)JPMorgan Chase & Co. lifted its stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 4,826,425.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 772,244 shares of the company's stock afteApril 26, 2025 | marketbeat.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average - Should You Sell?Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Above 50 Day Moving Average - What's Next?March 21, 2025 | marketbeat.comVistaGen at Stifel 2025: Pioneering Acute SAD TreatmentMarch 20, 2025 | investing.comVistagen to Present at the 2025 Anxiety and Depression Association ConferenceMarch 19, 2025 | businesswire.comVistagen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50 Day Moving Average - Should You Sell?Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below 50-Day Moving Average - Should You Sell?March 11, 2025 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50 Day Moving Average - Here's WhyVistagen Therapeutics (NASDAQ:VTGN) Stock Passes Above 50 Day Moving Average - Here's WhyFebruary 22, 2025 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call TranscriptFebruary 15, 2025 | msn.comVistaGen’s Earnings Call: Progress and ChallengesFebruary 14, 2025 | tipranks.comVistagen: Pherine Candidate Proof Of Concept Continues With Fifth IndicationFebruary 14, 2025 | seekingalpha.comStemPoint Capital LP's Strategic Acquisition of Vistagen Therapeutics Inc SharesFebruary 14, 2025 | gurufocus.comVistagen Therapeutics (NASDAQ:VTGN) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSVistagen Therapeutics (NASDAQ:VTGN - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%.February 14, 2025 | marketbeat.comVistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...February 14, 2025 | gurufocus.comQ3 2025 Vistagen Therapeutics Inc Earnings Call TranscriptFebruary 14, 2025 | gurufocus.comVistagen advances Phase 3 SAD trials with 2025 data readout targetFebruary 13, 2025 | msn.comVistagen reports Q3 EPS (46c) vs (22c) last yearFebruary 13, 2025 | markets.businessinsider.comEarnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net lossFebruary 13, 2025 | msn.comVistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comVistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. ...February 13, 2025 | gurufocus.comEarnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 ResultFebruary 12, 2025 | gurufocus.comVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50-Day Moving Average - Here's WhyVistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average - What's Next?February 12, 2025 | marketbeat.comVistagen granted USPTO patent for AV-101 to treat neuropathic painFebruary 6, 2025 | markets.businessinsider.comVistagen secures patent for non-opioid pain treatmentFebruary 6, 2025 | msn.comVistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025February 6, 2025 | businesswire.comVistagen Receives U.S. Patent for AV-101 to Treat Neuropathic PainFebruary 5, 2025 | businesswire.comVistagen Therapeutics (VTGN) to Release Quarterly Earnings on TuesdayVistagen Therapeutics (NASDAQ:VTGN) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports.February 4, 2025 | marketbeat.comVistagen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Increase in Short InterestVistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 658,100 shares, a growth of 46.2% from the December 31st total of 450,000 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 2.4 days.January 31, 2025 | marketbeat.comVistagen announces results from PH284 study in cancer cachexiaJanuary 15, 2025 | markets.businessinsider.comVistagen enrolls first patient in repeat dose study of fasedienolJanuary 10, 2025 | markets.businessinsider.comVistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety DisorderJanuary 10, 2025 | businesswire.comGreat Point Partners LLC Sells 855,263 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)Great Point Partners LLC decreased its stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 55.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 674,075 shares of the company's stock afteNovember 27, 2024 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for VistaGen Therapeutics (VTGN)November 22, 2024 | markets.businessinsider.comVistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest UpdateVistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 528,200 shares, a decrease of 18.1% from the October 15th total of 644,700 shares. Based on an average daily volume of 159,300 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.1% of the shares of the company are sold short.November 15, 2024 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call TranscriptNovember 11, 2024 | insidermonkey.com Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address VTGN Media Mentions By Week VTGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTGN News Sentiment▼0.330.69▲Average Medical News Sentiment VTGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTGN Articles This Week▼111▲VTGN Articles Average Week Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TNXP News NGNE News RNAC News ANNX News CGC News TSVT News DBVT News PVLA News CADL News CRDF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTGN) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
